Abstract
New biomarkers for the diagnosis of indeterminate lung nodules (IPN) suspicious for lung cancer are being developed regularly. Clinically useful new diagnostic tests for IPN requires improvement in post-test risk classification to reduce subsequent testing or time to diagnosis. Therefore, measuring the activity to a diagnosis is needed. In a collaboration between Lahey Hospital and Medical Center (LHMC), representing a large screening only population, Vanderbilt University Medical Center (VUMC), a tertiary referral center with incidental and screening discovered nodules, and OneFlorida Clinical Research Consortium, a statewide network with incidental nodules, we defined an algorithm to combine real world data (RWD) from electronic health records (EHR) to measure the clinical activity necessary to diagnose an IPN.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
